

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

## 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Oxfendazole / Oxyclozanide Formulation

**Supplier's company name, address and phone number**

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

## 2. HAZARDS IDENTIFICATION

**GHS classification of chemical product**

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure : Category 2 (Liver, Testis, Brain)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.

## Oxfendazole / Oxcyclozanide Formulation

Version 9.0      Revision Date: 2025/04/14      SDS Number: 7942510-00010      Date of last issue: 2024/09/28  
Date of first issue: 2021/03/19

H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

## Precautionary statements

: **Prevention:**

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.

P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Important symptoms and outlines of the emergency assumed

: Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
oxyclozanide	2277-92-1	>= 40 - < 50	9-1297
oxfendazole	53716-50-0	>= 20 - < 25	-
Starch, oxidized	65996-62-5	>= 10 - < 20	8-99
Magnesium stearate	557-04-0	>= 1 - < 10	2-611

**4. FIRST AID MEASURES**

**Oxfendazole / Oxcyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

**5. FIREFIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Chlorine compounds Nitrogen oxides (NO <sub>x</sub> ) Metal oxides Oxides of phosphorus
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Oxfendazole / Oxyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**7. HANDLING AND STORAGE****Handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

practice, based on the results of the workplace exposure assessment

Keep container tightly closed.

Minimize dust generation and accumulation.

Keep container closed when not in use.

Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Storage**

Conditions for safe storage : Keep in properly labelled containers.

Store locked up.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Starch, oxidized	65996-62-5	TWA (inhalable dust)	0.5 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable par-	3 mg/m <sup>3</sup>	ACGIH

## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

	ticulate mat- ter)		
--	-----------------------	--	--

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state : powder

Colour : white to off-white, light cream, cream

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

**Oxfendazole / Oxyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

Flammability (liquids)	:	Not applicable
Lower explosion limit and upper explosion limit / flammability limit		
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Decomposition temperature	:	No data available
pH	:	No data available
Evaporation rate	:	Not applicable
Auto-ignition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	Not applicable
Density and / or relative density		
Relative density	:	No data available
Density	:	0.88 g/cm <sup>3</sup>
Relative vapour density	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

---

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means.

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

Can react with strong oxidizing agents.

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****oxyclozanide:**

Acute oral toxicity	:	LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	:	LDLo (sheep): 10 mg/kg Application Route: Intravenous

**oxfendazole:**

Acute oral toxicity	:	LD50 (Rat): > 6,000 mg/kg  LD50 (Dog): 1,600 mg/kg  LD50 (sheep): 250 mg/kg
---------------------	---	---

**Magnesium stearate:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****oxyclozanide:**



## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

Remarks : Not classified due to lack of data.

**oxfendazole:**

Species : Rabbit  
Result : No skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****oxyclozanide:**

Remarks : Not classified due to lack of data.

**oxfendazole:**

Species : Rabbit  
Result : No eye irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****oxyclozanide:**

Exposure routes : Dermal  
Remarks : Not classified due to lack of data.

**Magnesium stearate:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****oxclozanide:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive  Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative  Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

**oxfendazole:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive

**Magnesium stearate:**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials  Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
-----------------------	--

**Oxfendazole / Oxclozanide Formulation**

Version 9.0	Revision Date: 2025/04/14	SDS Number: 7942510-00010	Date of last issue: 2024/09/28 Date of first issue: 2021/03/19
----------------	------------------------------	------------------------------	---

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****oxyclozanide:**

Remarks : Not classified due to lack of data.

**oxfendazole:**

Species : Rat  
Application Route : Oral  
Exposure time : 1 Years  
Symptoms : No adverse effects  
Target Organs : Liver

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Symptoms : No adverse effects  
Target Organs : Liver

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****oxyclozanide:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development  
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development  
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat

## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

		Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
		Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity, No teratogenic effects, No effects on fertility
Effects on foetal development	:	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
		Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
		Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity, Skeletal malformations
Reproductive toxicity - Assessment	:	Suspected of damaging the unborn child.

**oxfendazole:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility
		Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0.9 mg/kg body weight Target Organs: Liver Result: No effects on fertility
		Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months

## Oxfendazole / Oxyclozanide Formulation

Version 9.0	Revision Date: 2025/04/14	SDS Number: 7942510-00010	Date of last issue: 2024/09/28 Date of first issue: 2021/03/19
----------------	------------------------------	------------------------------	---

	Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects  Test Type: Embryo-foetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-foetal toxicity  Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities  Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

**Magnesium stearate:**

Effects on fertility	: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

**STOT - single exposure**

May cause damage to organs (Central nervous system) if swallowed.

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

**Components:****oxyclozanide:**

Exposure routes	: Oral
Target Organs	: Central nervous system
Assessment	: May cause damage to organs.

**STOT - repeated exposure**

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

**Components:****oxyclozanide:**

Target Organs	: Brain, Liver
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**oxfendazole:**

Exposure routes	: Oral
Target Organs	: Liver, Testis
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****oxyclozanide:**

Species	: Rat
NOAEL	: 9 mg/kg
LOAEL	: 44.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver, spleen, Adrenal gland
Symptoms	: Liver effects

Species	: Dog
NOAEL	: 5 mg/kg
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver
Symptoms	: blood effects, alteration in liver enzymes

**oxfendazole:**

Species	: Rat
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

Species	: Rat
NOAEL	: 3.8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis

Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver

Species	: Mouse
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver

Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland

Species	: Dog
NOAEL	: 13.5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

**Starch, oxidized:**

Species	: Rat
NOAEL	: 22,500 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

**Magnesium stearate:**

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

**Aspiration toxicity**

Not classified based on available information.

**Components:****oxyclozanide:**

|| Not applicable

**Experience with human exposure****Components:****oxyclozanide:**

|| Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****oxyclozanide:**|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

|| M-Factor (Acute aquatic toxicity) : 1

|| M-Factor (Chronic aquatic toxicity) : 1

**oxfendazole:**|| Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l  
Exposure time: 96 h  
  
LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l  
Exposure time: 96 h|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.059 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202|| Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201|| NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h



## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity)	:	10
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.023 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	1

**Magnesium stearate:**

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility
		NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

**Persistence and degradability****Components:****oxcyclozanide:**

Stability in water	:	Hydrolysis: 50 %(156 d) Method: OECD Test Guideline 111
--------------------	---	--

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	2025/04/14	7942510-00010	2024/09/28
			Date of first issue: 2021/03/19

---

**oxfendazole:**

Stability in water : Hydrolysis: < 5 %(4 d)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3.99  
pH: 7  
Method: OECD Test Guideline 107

**oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****oxyclozanide:**

Distribution among environmental compartments : log Koc: 4.83  
Method: OECD Test Guideline 106

**oxfendazole:**

Distribution among environmental compartments : log Koc: 3.2

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

---

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**Oxfendazole / Oxyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (oxfendazole, oxyclozanide)
Class	: 9
Packing group	: III
Labels	: 9
Environmentally hazardous	: yes

**IATA-DGR**

UN/ID No.	: UN 3077
Proper shipping name	: Environmentally hazardous substance, solid, n.o.s. (oxfendazole, oxyclozanide)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 956
Packing instruction (passenger aircraft)	: 956
Environmentally hazardous	: yes

**IMDG-Code**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (oxfendazole, oxyclozanide)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

<b>ERG Code</b>	: 171
-----------------	-------

## Oxfendazole / Oxcyclozanide Formulation

Version 9.0	Revision Date: 2025/04/14	SDS Number: 7942510-00010	Date of last issue: 2024/09/28 Date of first issue: 2021/03/19
----------------	------------------------------	------------------------------	---

## 15. REGULATORY INFORMATION

**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Substances Subject to be Notified Names**

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>=1 - <10	-

**Substances Subject to be Indicated Names**

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
Magnesium stearate	-

**Skin and Eye Damage Substances (ISHL MO Art. 594-2)**

Not applicable

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

**Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

**Ordinance on Prevention of Lead Poisoning**

Not applicable

**Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

**Oxfendazole / Oxcyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

**Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

**Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

**Poisonous and Deleterious Substances Control Law**

Not applicable

**Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

**High Pressure Gas Safety Act**

Not applicable

**Explosive Control Law**

Not applicable

**Vessel Safety Law**

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

**Aviation Law**

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

**Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Classified as marine pollutant

**Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**16. OTHER INFORMATION**

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

**Oxfendazole / Oxcyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
9.0	2025/04/14	7942510-00010	Date of first issue: 2021/03/19

---

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN